Complex CVR Will Enable Genzyme And Sanofi Shareholders To Share Potential Upside For Lemtrada

A six-part contingent value right included along with Sanofi-Aventis’ cash payment of $74 a share (about $20.1 billion) for Genzyme should enable both companies’ shareholders to share in the potential upside of Lemtrada (alemtuzumab) if it is approved as a treatment for multiple sclerosis.